register

News & Trends - Pharmaceuticals

TGA approves Pfizer-BioNTech COVID-19 vaccine

Health Industry Hub | January 25, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Pfizer Australia and BioNTech today announced that the Therapeutic Goods Administration (TGA) in Australia has granted Provisional Approval for their COVID-19 mRNA vaccine COMIRNATY™.

The distribution of the vaccine in Australia will be prioritised by the Department of Health according to the populations identified in guidance from the ATAGI (Australian Technical Advisory Group on Immunisation) COVID-19 Working Group.

“Today’s Provisional Approval in Australia marks an historic moment in the fight against COVID-19. It further affirms Pfizer’s commitment to deliver on its promise to safely bring to Australians a high quality vaccine against this virus,” said Anne Harris, Pfizer Australia and New Zealand Managing Director.

“We commend the TGA for its careful assessment of COMIRNATY™. We thank both the Commonwealth Government and the Department of Health for their strong partnership to bring our vaccine to Australians. We are proud to be part of this breakthrough which was made possible through unparalleled collaboration between companies, governments, regulators, public health bodies, and the academic and scientific communities coming together urgently to find solutions to the pandemic”, Ms Harris said.

“It is encouraging to see that our mRNA vaccine is now approved in Australia. The number of countries authorising the use of our vaccine is steadily increasing. This is important in order to support addressing this pandemic,” said Sean Marett, Chief Business Officer and Chief Commercial Officer at BioNTech.

“Together with our partner Pfizer, we are looking forward to shipping the vaccines to Australia”, Mr Marrett said.

Prime Minister Scott Morrison said the TGA approval was an important step in the fight against COVID-19.

“I welcome the TGA’s approval of the Pfizer vaccine, with our own Australian experts finding it is safe, effective and of a high standard,” the Prime Minister said.

“Australians should take confidence in the thorough and careful approach taken by our world-class safety regulator. Our priority has always been to keep Australians safe and protect lives and livelihoods. Today’s approval is another big step forward for our community, particularly in the protection of our most vulnerable people.”

The TGA’s decision is based on a rolling submission including data from the Phase 3 clinical study, which demonstrated a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective), and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose.

The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol. Efficacy was consistent across age, gender, race and ethnicity demographics, with an observed efficacy in adults age 65 and over, of more than 94%. In the trial, COMIRNATY™. was generally well tolerated with no safety concerns reported by the Data Monitoring Committee to date.

Minister for Health Greg Hunt said the-world class regulators at the TGA have been working tirelessly to introduce a safe and effective COVID-19 vaccine in Australia.

“The TGA’s processes are I believe the best in the world and we have ensured that they are thorough. The TGA has placed safety above all else. Australia’s high bar has been met; the vaccine has been approved as effective in stopping severe disease. I thank all those involved in the development and assessment of this COVID-19 vaccine, including the researchers, Pfizer, BioNTech and the medical experts at the TGA who have worked around the clock and over Christmas. This approval and the upcoming roll out of the vaccine will play an important part in our ability to manage the pandemic in 2021,”Minister Hunt said.

Pfizer and BioNTech previously announced an agreement with the Australian government on 5 November 2020 to supply 10 million doses of the mRNA-based vaccine COMIRNATY™ once approved. Dose deliveries will occur throughout 2021 in accordance with the terms of the supply agreement.

The vaccine has now been granted a conditional marketing authorization, emergency use authorisation, temporary authorisation or provisional approval in a total of more than 50 countries.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Johnson & Johnson breaking down barriers to gender equality

Johnson & Johnson breaking down barriers to gender equality

Health Industry Hub | February 26, 2021 |

MedTech News: The Johnson & Johnson Family of Companies in Australia is pleased to announce that the company has been […]

More


Human Resources

Human Resource Management - National gender pay gap drops to 13.4%

National gender pay gap drops to 13.4%

Health Industry Hub | February 26, 2021 |

Human Resources: The Workplace Gender Equality Agency announced today that that national gender pay gap has dropped to 13.4%, a decline […]

More


News & Trends - Medical Technology

MedTech News - Philips one of first MedTechs to become carbon neutral

Philips, one of first MedTechs to become carbon neutral

Health Industry Hub | February 26, 2021 |

MedTech News: Philips Healthcare Australia, a global leader in health technology, has successfully met all the targets set out in […]

More


Social Responsibility

Social Responsibility and Community Engagement - The race to win the 2021 Medicines Australia, Kosi Pharma-Cup

The race to win the 2021 Medicines Australia Kosi Pharma-Cup

Health Industry Hub | February 26, 2021 |

The countdown is on for Rare Cancer Australia’s Kosi Challenge and the battle to win the Pharma-Cup sponsored by Medicines […]

More